Showing results (551-560 of 834) with videos related to

Sort By:
Pageof 84
Diabetes Care|July 3, 2019
Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 DiabetesSascha Pilemann-Lyberg, Daniel Guldager Kring Rasmussen, Tine Willum Hansen, et al.
Advances in Therapy|May 30, 2026
Defining the Roles of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Management of Chronic Kidney Disease in Adults with Type 2 Diabetes With or Without Overweight/Obesity: An International Delphi ConsensusYehuda Handelsman, Alice Y Y Cheng, Gian Paolo Fadini, et al.
Diabetes, Obesity & Metabolism|September 28, 2021
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trialPeter Rossing, Rajiv Agarwal, Stefan D Anker, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 2, 2024
Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6Ellen M Apperloo, David Z I Cherney, Anja Birk Kuhlman, et al.
Scientific Reports|September 9, 2024
Transcutaneous vagus nerve stimulation has no anti-inflammatory effect in diabetesTina Okdahl, Huda Kufaishi, Ditte Kornum, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 9, 2024
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysisBertram Pitt, Rajiv Agarwal, Stefan D Anker, et al.
Kidney International|April 23, 2025
Analysis of the prespecified FIDELITY pooled patient dataset examined the efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rateSankar D Navaneethan, Stefan D Anker, Gerasimos Filippatos, et al.
Diabetes, Obesity & Metabolism|July 29, 2025
The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre studyElisabeth B Stougaard, Mads R Andersen, Jonatan I Bagger, et al.
BMJ Open Diabetes Research & Care|September 14, 2021
Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trialEmilie H Zobel, Asger Wretlind, Rasmus S Ripa, et al.
Cardiovascular Diabetology|November 26, 2022
The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitusCarlos Puig-Jové, Josep Julve, Esmeralda Castelblanco, et al.
Pageof 84